Total Lipids In Medium Hdl
Introduction
Background
Total lipids, particularly those associated with high-density lipoprotein (HDL), are critical determinants of cardiovascular disease (CVD) and contribute to overall morbidity . While the study involved a meta-analysis of several genome-wide association studies and subsequent replication analyses, the current sample sizes may still be insufficient to detect all genetic factors, particularly those with smaller effect sizes or lower frequencies within the population. This limitation implies that a significant portion of the genetic landscape influencing lipid traits may remain undiscovered, thus preventing a complete understanding of the complex polygenic architecture underlying dyslipidemia.
Generalizability and Phenotypic Scope
A primary limitation of these studies is the demographic specificity of the cohorts, which predominantly comprised individuals of European ancestry. [1] This narrow ancestral focus restricts the direct generalizability of the findings to more diverse populations, as the genetic architecture, allele frequencies, and environmental interactions influencing lipid-related traits can vary significantly across different ethnic groups. Consequently, the identified genetic variants and their estimated effect sizes may not be universally applicable or representative for individuals from other ancestral backgrounds. Furthermore, the investigations specifically focused on fasting blood lipid phenotypes. [1] While crucial for baseline assessment, this approach may not fully capture the dynamic complexity of lipid metabolism, such as post-prandial responses, diurnal variations, or the intricate interplay of various lipid subclasses, potentially limiting the comprehensive phenotypic assessment.
Variants
The regulation of total lipids in medium HDL is a complex process influenced by numerous genetic factors, with several key variants affecting enzymes and proteins crucial for lipoprotein metabolism. Variants near LIPC (Hepatic Lipase), such as rs1077835, are associated with HDL cholesterol levels. LIPC is an enzyme that hydrolyzes phospholipids and triglycerides in lipoproteins, primarily impacting HDL remodeling and clearance. For instance, the minor T allele of another LIPC variant, rs10468017, is linked to lower LIPC expression and higher HDL cholesterol concentrations. [2] Similarly, variants in or near LPL (Lipoprotein Lipase), like rs117026536, significantly influence triglyceride breakdown and overall lipoprotein levels. LPL is crucial for hydrolyzing triglycerides in circulating chylomicrons and very-low-density lipoproteins, which in turn affects the availability of lipids for HDL formation and remodeling; studies report that LPL variants have strong associations with both HDL cholesterol and triglyceride levels. [3] Another important locus is CETP (Cholesteryl Ester Transfer Protein), where variants like rs9989419 in the HERPUD1-CETP region are associated with HDL cholesterol levels. CETP mediates the transfer of cholesteryl esters from HDL to triglyceride-rich lipoproteins, impacting the size and composition of HDL particles, with its inhibition typically leading to higher HDL levels. [3]
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs72786786 rs183130 |
HERPUD1 - CETP | depressive symptom measurement, non-high density lipoprotein cholesterol measurement HDL cholesterol change measurement, physical activity total cholesterol measurement, high density lipoprotein cholesterol measurement free cholesterol measurement, high density lipoprotein cholesterol measurement phospholipid amount, high density lipoprotein cholesterol measurement |
| rs2043085 rs2414578 |
ALDH1A2 | metabolic syndrome high density lipoprotein cholesterol measurement level of phosphatidylcholine level of phosphatidylethanolamine level of diglyceride |
| rs1065853 | APOE - APOC1 | low density lipoprotein cholesterol measurement total cholesterol measurement free cholesterol measurement, low density lipoprotein cholesterol measurement protein measurement mitochondrial DNA measurement |
| rs6073972 | ZNF335 | high density lipoprotein cholesterol measurement triglyceride measurement, blood VLDL cholesterol amount total lipids in medium hdl measurement mean corpuscular hemoglobin erythrocyte volume |
| rs1077835 | ALDH1A2, LIPC | triglyceride measurement high density lipoprotein cholesterol measurement level of phosphatidylcholine level of phosphatidylethanolamine total cholesterol measurement |
| rs2156552 | SMUG1P1 - ACAA2 | high density lipoprotein cholesterol measurement low density lipoprotein cholesterol measurement, alcohol consumption quality alcohol consumption quality, high density lipoprotein cholesterol measurement low density lipoprotein cholesterol measurement alcohol drinking, high density lipoprotein cholesterol measurement |
| rs429358 | APOE | cerebral amyloid deposition measurement Lewy body dementia, Lewy body dementia measurement high density lipoprotein cholesterol measurement platelet count neuroimaging measurement |
| rs15285 | LPL | blood pressure trait, triglyceride measurement waist-hip ratio coronary artery disease level of phosphatidylcholine sphingomyelin measurement |
| rs77960347 | LIPG | apolipoprotein A 1 measurement level of phosphatidylinositol total cholesterol measurement high density lipoprotein cholesterol measurement low density lipoprotein cholesterol measurement |
| rs9304381 rs117687565 |
LIPG - SMUG1P1 | depressive symptom measurement, non-high density lipoprotein cholesterol measurement HDL cholesterol change measurement, physical activity linoleic acid measurement esterified cholesterol measurement free cholesterol measurement |
Lipid Synthesis and Transport Pathways
Variations in genes involved in fatty acid synthesis and core lipoprotein components also profoundly affect lipid profiles. The FADS1 and FADS2 genes encode fatty acid desaturases, enzymes critical for producing polyunsaturated fatty acids. The variant rs174564 within the FADS1-FADS2-FADS3 cluster is notably associated with both HDL cholesterol and triglycerides. [2] Specifically, an allele linked to increased FADS1 and FADS3 expression correlates with higher HDL cholesterol and lower triglycerides, indicating its role in regulating plasma lipid composition. [2] Meanwhile, the APOE-APOC1 gene cluster is central to the metabolism of chylomicrons and very-low-density lipoproteins. APOE acts as a ligand for lipoprotein receptors, facilitating the uptake of triglyceride-rich lipoprotein remnants, while APOC1 can modulate this process. Variants in this cluster, such as rs1065853, are well-established determinants of LDL cholesterol levels, and also influence HDL and triglyceride concentrations due to their broad impact on lipoprotein transport and clearance. Another gene, ALDH1A2, involved in retinoid acid metabolism, can indirectly influence lipid homeostasis; while specific functional details of its rs1601935 variant on medium HDL are still emerging, its presence among key lipid-associated loci suggests a role in broader metabolic regulation.
Other Lipid Modulators and Regulatory Elements
Further genetic variations contribute to the intricate landscape of lipid metabolism, including those affecting lipid transfer proteins and less conventional metabolic regulators. The PLTP (Phospholipid Transfer Protein) gene, where rs6073958 is identified in the PLTP-PCIF1 region, plays a role in HDL remodeling by facilitating the transfer of phospholipids and cholesterol between lipoproteins; increased PLTP activity can lead to lower HDL cholesterol. Similarly, ANGPTL4 (Angiopoietin Like 4) is known to inhibit LPL activity, thereby reducing triglyceride clearance and influencing HDL levels; the variant rs116843064 in this gene may therefore impact circulating lipid profiles. Moreover, the variant rs964184, listed under ZPR1, is strongly associated with triglyceride concentrations and is located near the APOA5-APOA4-APOC3-APOA1 cluster, a critical region for triglyceride-rich lipoprotein metabolism. [3] This proximity suggests rs964184 may influence the expression or function of genes within this powerful lipid-regulating cluster, leading to an increase in triglycerides per specific allele. [3] Lastly, rs79600951 is located in NUP93, a gene primarily known for its role in the nuclear pore complex; while its direct mechanism in lipid metabolism is less defined, variations can sometimes exert indirect effects on metabolic processes.
Classification, Definition, and Terminology
Defining Total Lipids within Medium HDL Particles
Total lipids in medium high-density lipoprotein (HDL) refer to the entire complement of fatty substances, including cholesterol esters, triglycerides, phospholipids, and free cholesterol, carried specifically within the medium-sized fraction of HDL particles in the bloodstream. HDL, often known as "good cholesterol," plays a critical role in reverse cholesterol transport, removing excess cholesterol from peripheral tissues and returning it to the liver for excretion or recycling. Characterizing the total lipid content of specific HDL subfractions, such as medium HDL, allows for a more nuanced understanding of lipid metabolism and its potential implications for metabolic health. [4] This trait is considered a metabolic trait, contributing to the overall metabolic profile of an individual. [4]
Measurement Approaches and Operational Definitions
The assessment of total lipids in medium HDL is an operational definition derived from advanced lipoprotein profiling, which differentiates HDL particles by size and density. While the general "serum lipid levels" are routinely measured to assess overall cholesterol, including total cholesterol, HDL cholesterol, and triglycerides, specific quantification of lipids within HDL subfractions requires more specialized analytical techniques. [5] These methods allow researchers to define and measure distinct lipid components within medium HDL particles, providing detailed insights into lipid transport dynamics beyond standard lipid panel measurements. Such precise measurement approaches are vital for research criteria aimed at identifying specific metabolic phenotypes and understanding their genetic and environmental influences. [5]
Classification of Related Metabolic Traits and Conditions
Total lipids in medium HDL are classified as a component within the broader framework of metabolic traits, which encompasses various physiological characteristics related to energy metabolism and cardiovascular health. [4] This trait exists within the complex system of lipid metabolism, a fundamental biological process involving the synthesis, transport, and breakdown of fats. Disruptions in lipid metabolism, including alterations in HDL composition, are frequently associated with metabolic syndrome, a cluster of conditions that includes abdominal obesity, high blood pressure, high blood sugar, and abnormal cholesterol or triglyceride levels. [6] The presence and concentration of total lipids in medium HDL, therefore, contribute to a dimensional approach in assessing an individual's risk for metabolic syndrome and related cardiometabolic disorders.
Causes
Genetic Architecture and Polygenic Influences
The concentration of total lipids within medium high-density lipoprotein (HDL) is significantly shaped by an individual's genetic makeup. Research indicates that dyslipidemia, a broader condition encompassing altered lipid profiles, is influenced by common genetic variants found at numerous loci across the genome. [1] These common single-nucleotide polymorphisms (SNPs) do not act in isolation but rather in concert, collectively impacting plasma levels of high-density lipoprotein cholesterol. [7] This highlights a polygenic basis, where multiple genes and their variants each contribute a small effect, cumulatively determining an individual's predisposition to certain lipid profiles.
The collective impact of these genetic variants creates a complex architecture that underlies variability in lipid traits. Studies have mapped the genetic architecture of gene expression, including those relevant to lipid metabolism in organs like the human liver. [8] Such genetic influences on gene expression ultimately translate into varying levels and compositions of circulating lipoproteins, including the total lipids present in medium HDL, by affecting the synthesis, breakdown, and transport pathways.
Specific Gene Variants and Their Mechanisms
Specific genes and their variants play direct roles in the metabolism and composition of HDL. For instance, genetic analysis in founder populations has identified associations between genes such as _endothelin-1_ and high-density lipoprotein cholesterol levels. [9] Such findings suggest that certain genetic variants can significantly alter lipid profiles within specific populations.
Further, the _hepatocyte nuclear factor-1alpha_ (_HNF1A_) gene contains variants like G319S, which have been associated with plasma lipoprotein variation in specific groups, such as the Canadian Oji-Cree. [10] These genetic factors directly influence the regulatory pathways involved in lipoprotein metabolism, thereby affecting the total lipids contained within medium HDL particles. These variants demonstrate how specific genetic differences can manifest in observable variations in an individual's lipid profile.
Biological Background
Lipoprotein Metabolism and Function
Lipids, including cholesterol and triglycerides, are crucial for cell structure, energy storage, and hormone production, but their transport in the aqueous environment of blood requires packaging into lipoproteins. High-density lipoprotein (HDL) plays a vital role in reverse cholesterol transport, a pathway that removes excess cholesterol from peripheral tissues and returns it to the liver for excretion or recycling. Conversely, low-density lipoprotein (LDL) is primarily responsible for delivering cholesterol to peripheral cells, and its accumulation can lead to arterial plaque formation. [3] The dynamic interplay among various lipoproteins, including HDL and LDL, and their constituent total lipids, is tightly regulated by a complex network of enzymes, receptors, and apolipoproteins that ensure metabolic balance throughout the body. [3]
This intricate system involves multiple organs and cellular processes, with the liver and intestines being central to the synthesis and secretion of apolipoproteins and the assembly of lipoprotein particles. For instance, apolipoprotein C-III (APOC3), secreted from the liver and intestines, is a component of both HDL and apoB-containing lipoproteins. APOC3 not only impairs the catabolism and hepatic uptake of apoB-containing lipoproteins but also appears to enhance the catabolism of HDL, influencing the overall lipid profile. [11] Maintaining optimal levels of total lipids within these lipoprotein classes is critical for systemic health, as disruptions can have far-reaching consequences.
Genetic Determinants of Lipid Levels
The circulating levels of lipids in the blood exhibit high heritability, indicating a significant genetic influence on an individual's lipid profile. [12] Genome-wide association studies (GWAS) have identified numerous genetic loci, including specific genes and gene clusters, that contribute to variations in serum HDL cholesterol, LDL cholesterol, and triglycerides. [12] These genes encode a diverse array of proteins involved in nearly every aspect of lipid metabolism, from the formation and activity of lipoproteins to their eventual turnover. [3]
Among the implicated genes are those encoding key apolipoproteins such as APOE, APOB, APOA5, APOA4, APOC3, APOC1, and APOA1, which are integral structural and functional components of lipoprotein particles. [12] Other genes, like ABCA1, code for cholesterol transporters, while CETP is involved in cholesterol ester transport, highlighting the precise molecular mechanisms governed by these genetic factors. [3] Although many common variants have been identified, they currently explain only a small fraction of the total variation in population lipid concentrations, suggesting that a substantial portion of the genetic landscape remains to be characterized. [12]
Key Proteins and Regulatory Mechanisms
Lipid homeostasis relies on the coordinated action of a wide range of proteins, including enzymes, receptors, and transcription factors. Enzymes such as lipoprotein lipase (LPL), hepatic lipase (LIPC), and endothelial lipase (LIPG) are critical for the hydrolysis of triglycerides in lipoproteins, thereby influencing the composition and size of these particles. [3] HMGCR, encoding HMG-CoA reductase, catalyzes an early and rate-limiting step in cholesterol biosynthesis, and common single nucleotide polymorphisms (SNPs) in this gene can affect alternative splicing, impacting its function. [13]
Regulatory proteins also play crucial roles in maintaining lipid balance. For example, ANGPTL4 functions as an inhibitor of lipoprotein lipase, directly affecting triglyceride clearance. [1] Transcription factors like MLXIPL bind to and activate specific motifs in the promoters of triglyceride synthesis genes, while MAFB interacts with LDL-related proteins, underscoring the complex regulatory networks that govern lipid metabolism. [3] The presence of a null mutation in human APOC3, which reduces the protein's levels, has been shown to confer a favorable plasma lipid profile and provide apparent protection against cardiovascular events. [11]
Lipids and Cardiovascular Disease Risk
Abnormal levels of circulating lipids, collectively known as dyslipidemia, are well-established and significant risk factors for cardiovascular disease (CVD) and related morbidity. [12] Coronary artery disease (CAD) and stroke, which are leading causes of mortality and disability globally, are fundamentally linked to atherosclerosis, a condition characterized by the progressive deposition of LDL cholesterol within arterial walls. [3] Therefore, managing lipid levels is a primary strategy for preventing these life-threatening conditions.
While high concentrations of LDL cholesterol are directly associated with an increased risk of CAD, elevated levels of HDL cholesterol are consistently linked to a decreased risk. [3] Research indicates that even small changes in lipoprotein-associated lipid concentrations can have a notable impact on cardiovascular risk; for instance, a 1% decrease in LDL cholesterol can reduce coronary heart disease risk by approximately 1%, while a 1% increase in HDL cholesterol can reduce risk by about 2%. [3] These relationships highlight the importance of understanding the biological mechanisms that influence total lipids in various lipoprotein fractions, including HDL, for developing effective prevention and treatment strategies for CVD.
Pathways and Mechanisms
Metabolic Pathways of Lipid Homeostasis
The regulation of total lipids in medium high-density lipoprotein (HDL) involves complex metabolic pathways governing synthesis, transport, and catabolism of various lipid species. Key enzymes in cholesterol biosynthesis include HMGCR and MVK, which catalyzes an early step in the mevalonate pathway [12]. [3] Conversely, MMAB plays a role in cholesterol degradation, ensuring balanced cholesterol levels. [3] Triglyceride synthesis is significantly influenced by MLXIPL, a transcription factor that binds and activates specific motifs in the promoters of triglyceride synthesis genes [3]. [14]
Lipoprotein lipases, such as LPL, LIPC, and LIPG, are crucial for the catabolism of triglycerides within lipoproteins [12]. [3] Their activity is tightly controlled by inhibitors like ANGPTL3 and ANGPTL4, with ANGPTL4 notably inhibiting lipoprotein lipase in studies [1], [3]. [15] The ABCA1 transporter facilitates cholesterol efflux from cells, a critical initial step in the formation of HDL particles [12]. [3] Furthermore, the cholesteryl ester transfer protein (CETP) mediates the transfer of cholesteryl esters and triglycerides between different lipoprotein classes, profoundly influencing HDL composition and metabolism [12]. [3]
Lipoprotein Assembly and Receptor-Mediated Dynamics
Plasma lipoproteins, including HDL, are complex assemblies of lipids and apolipoproteins, whose interactions dictate their structure, function, and metabolic fate. Apolipoproteins such as APOA1, APOA5, APOC3, APOB, and APOE are integral components, contributing to lipoprotein stability, enzyme activation, and receptor recognition [3], [12]. [11] For instance, APOC3 is found on both HDL and apoB-containing lipoprotein particles and has been shown to impair the catabolism and hepatic uptake of apoB-containing lipoproteins, while also appearing to enhance the catabolism of HDL [11]. [16]
The cellular uptake and clearance of lipoproteins are predominantly mediated by specific receptors. The low-density lipoprotein receptor (LDLR) plays a central role in the endocytosis of apoB- and apoE-containing lipoproteins [12]. [3] Its levels are, in turn, regulated by PCSK9, a protein that leads to the degradation of the LDLR. [12] Additionally, SORT1 has been identified as a possible endocytic receptor for lipoprotein lipase, indicating a potential role in mediating the cellular processing and degradation of this key enzyme [3]. [17]
Transcriptional and Post-Translational Regulatory Mechanisms
Gene regulation and protein modification are fundamental control points in lipid metabolism, influencing the expression and activity of enzymes and transporters. The transcription factor MLXIPL directly impacts triglyceride levels by activating the promoters of genes involved in their synthesis, thus exerting significant control over metabolic flux [3]. [14] Cholesterol synthesis and degradation enzymes, such as MVK and MMAB, are known to be regulated by SREBP2, a key transcription factor in cholesterol homeostasis. [3]
Post-translational modifications also play a crucial role in fine-tuning lipoprotein function and interaction. For example, GALNT2 encodes a glycosyltransferase that could potentially modify lipoproteins or their receptors. [3] Such glycosylation events can alter protein stability, cellular localization, or receptor binding affinity, thereby impacting lipid metabolism. The apolipoprotein APOC3 provides an example of post-translational regulatory impact, as its presence impairs lipoprotein catabolism and hepatic uptake, leading to higher circulating lipid levels. [11]
Systems-Level Integration and Pathophysiological Significance
The intricate network of lipid metabolic pathways demonstrates significant crosstalk and hierarchical regulation, where alterations in one pathway can have emergent effects on overall lipid profiles and disease risk. For instance, common variants near genes like CETP, LPL, LIPC, ABCA1, LIPG, and GALNT2 are consistently associated with HDL cholesterol levels, highlighting their integrated roles in HDL metabolism. [3] Dysregulation within these pathways is a hallmark of cardiovascular disease, with elevated low-density lipoprotein (LDL) cholesterol being a primary driver of atherosclerosis, while high HDL cholesterol is associated with a decreased risk. [3]
Genetic studies have revealed that common loci influencing lipid levels, such as those involving APOA5 and GCKR for triglycerides, or LDLR and APOE/APOC cluster for LDL cholesterol, collectively explain only a fraction of the variation in lipid concentrations within the population [12]. [3] This suggests a complex polygenic architecture and significant environmental influences on total lipid levels. The identification of null mutations in genes like APOC3, which confer a favorable plasma lipid profile and apparent cardioprotection, underscores the potential for targeting specific pathways for therapeutic intervention. [11] Such findings contribute to understanding the causal pathways between genetic variants, circulating lipid levels, and disease outcomes, guiding preventive strategies like statin treatments or dietary changes. [12]
References
[1] Kathiresan, S et al. "Common variants at 30 loci contribute to polygenic dyslipidemia." Nat Genet, vol. 41, no. 1, 2009, pp. 56-65.
[2] Kathiresan S, et al. "Common variants at 30 loci contribute to polygenic dyslipidemia." Nat Genet, vol. 40, no. 11, 2008, pp. 1293-1301.
[3] Willer CJ, et al. "Newly identified loci that influence lipid concentrations and risk of coronary artery disease." Nat Genet, vol. 40, no. 2, 2008, pp. 161-9.
[4] Sabatti, C, et al. "Genome-wide association analysis of metabolic traits in a birth cohort from a founder population." Nat Genet, vol. 40, no. 2, 2008, pp. 106-112.
[5] Heller, D. A., et al. "Genetic and environmental influences on serum lipid levels in twins." New England Journal of Medicine, vol. 328, 1993, pp. 1150–1156.
[6] Alberti, K. G., et al. "Metabolic syndrome-a new world-wide definition."
[7] Spirin V, et al. "Common single-nucleotide polymorphisms act in concert to affect plasma levels of high-density lipoprotein cholesterol." Am. J. Hum. Genet., vol. 81, no. 6, 2007, pp. 1298–1303.
[8] Schadt EE, et al. "Mapping the genetic architecture of gene expression in human liver." PLoS Biol., vol. 6, no. 5, 2008, p. e107.
[9] Pare G, et al. "Genetic analysis of 103 candidate genes for coronary artery disease and associated phenotypes in a founder population reveals a new association between endothelin-1 and high-density lipoprotein cholesterol." Am. J. Hum. Genet., vol. 80, no. 4, 2007, pp. 673–682.
[10] Hegele RA, et al. "The private hepatocyte nuclear factor-1alpha G319S variant is associated with plasma lipoprotein variation in Canadian Oji-Cree." Arterioscler. Thromb. Vasc. Biol., vol. 20, no. 1, 2000, pp. 217–222.
[11] Pollin, TI et al. "A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection." Science, vol. 322, no. 5908, 2008, pp. 1702-05.
[12] Aulchenko, YS et al. "Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts." Nat Genet, vol. 41, no. 1, 2009, pp. 47-55.
[13] Burkhardt, R et al. "Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13." Arterioscler Thromb Vasc Biol, vol. 28, no. 12, 2008, pp. 2097-104.
[14] Kooner, JS et al. “Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides.” Nat Genet, vol. 40, no. 2, 2008, pp. 149-151.
[15] Yoshida, K et al. “Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase.” J Lipid Res, vol. 43, no. 10, 2002, pp. 1770-1772.
[16] Aalto-Setala, K et al. “Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.” J Clin Invest, vol. 90, no. 5, 1992, pp. 1889-1900.
[17] Nielsen, MS et al. “Sortilin/neurotensin receptor-3 binds and mediates degradation of lipoprotein lipase.” J Biol Chem, vol. 274, no. 13, 1999, pp. 8832-8836.